These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 29873091)

  • 1. Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition.
    Goncalves J; Santos M; Acurcio R; Iria I; Gouveia L; Matos Brito P; Catarina Cunha-Santos A; Barbas A; Galvão J; Barbosa I; Aires da Silva F; Alcobia A; Cavaco M; Cardoso M; Delgado Alves J; Carey JJ; Dörner T; Eurico Fonseca J; Palmela C; Torres J; Lima Vieira C; Trabuco D; Fiorino G; Strik A; Yavzori M; Rosa I; Correia L; Magro F; D'Haens G; Ben-Horin S; Lakatos PL; Danese S
    Aliment Pharmacol Ther; 2018 Sep; 48(5):507-522. PubMed ID: 29873091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
    Ben-Horin S; Yavzori M; Benhar I; Fudim E; Picard O; Ungar B; Lee S; Kim S; Eliakim R; Chowers Y
    Gut; 2016 Jul; 65(7):1132-8. PubMed ID: 25897019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.
    Fiorino G; Ruiz-Argüello MB; Maguregui A; Nagore D; Correale C; Radice S; Gilardi D; Allocca M; Furfaro F; Martínez A; Danese S
    Inflamm Bowel Dis; 2018 Feb; 24(3):601-606. PubMed ID: 29462398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
    Radin M; Sciascia S; Roccatello D; Cuadrado MJ
    BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.
    Ratnakumaran R; To N; Gracie DJ; Selinger CP; O'Connor A; Clark T; Carey N; Leigh K; Bourner L; Ford AC; Hamlin PJ
    Scand J Gastroenterol; 2018 Jun; 53(6):700-707. PubMed ID: 29687730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
    Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L; Peyrin-Biroulet L
    Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
    J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile.
    Danese S; Fiorino G
    Curr Med Chem; 2019; 26(2):280-287. PubMed ID: 29756565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease.
    Mahmmod S; Schultheiss JPD; van Bodegraven AA; Dijkstra G; Gilissen LPL; Hoentjen F; Lutgens MWMD; Mahmmod N; van der Meulen-de Jong AE; Smits LJT; Tan ACITL; Oldenburg B; Fidder HH
    Inflamm Bowel Dis; 2021 Nov; 27(12):1954-1962. PubMed ID: 33538298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease.
    Martín-Gutiérrez N; Sánchez-Hernández JG; Rebollo N; Pordomingo AF; Muñoz F; Otero MJ
    Eur J Hosp Pharm; 2022 Jul; 29(4):222-227. PubMed ID: 33115797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
    Jørgensen KK; Olsen IC; Goll GL; Lorentzen M; Bolstad N; Haavardsholm EA; Lundin KEA; Mørk C; Jahnsen J; Kvien TK;
    Lancet; 2017 Jun; 389(10086):2304-2316. PubMed ID: 28502609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.
    Buurman DJ; Blokzijl T; Festen EAM; Pham BT; Faber KN; Brouwer E; Dijkstra G
    PLoS One; 2018; 13(12):e0208922. PubMed ID: 30533022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study.
    Smits LJT; van Esch AAJ; Derikx LAAP; Boshuizen R; de Jong DJ; Drenth JPH; Hoentjen F
    Inflamm Bowel Dis; 2019 Jan; 25(1):172-179. PubMed ID: 29947795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars.
    Pouillon L; Allocca M; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2018 Sep; 48(5):574-575. PubMed ID: 30156324
    [No Abstract]   [Full Text] [Related]  

  • 19. Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn's Disease Comparing, between CT-P13 and Originator Infliximab.
    Park J; Cheon JH; Lee KM; Kim YH; Ye BD; Eun CS; Kim SH; Lee SH; Lee JH; Schreiber S
    Gut Liver; 2023 May; 17(3):430-440. PubMed ID: 35975641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
    Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
    J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.